Nanocarriers for the simultaneous co-delivery of therapeutic genes and anticancer drugs

Current Pharmaceutical Biotechnology

Volumn 13, Issue 7, 2012, Pages 1317-1331

  Choudhury, Nazia N ^a   He, Huixin ^a  

^a Rutgers University   (United States)

Author keywords

Cancer; Co delivery; Drug delivery; Liposomes; Mesoporous silica nanoparticles; Nanocarriers; siRNA

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; COPOLYMER; DENDRIMER; DIMETHYLAMINOETHYL METHACRYLATE POLY(3 CAPROLACTONE)DIMETHYL AMINOETHYL METHACRYLATE; DOXORUBICIN; FLUOROURACIL; GONADORELIN; LIPOSOME; MACROGOL; MESOPOROUS SILICON DIOXIDE NANOPARTICLE; MICRORNA 21; MULTIDRUG RESISTANCE PROTEIN 1; NANOCARRIER; NANOPARTICLE; OLIGONUCLEOTIDE; PACLITAXEL; PEGYLATED LIPOSOME; PLASMID DNA; POLY(ETHYLENIMINE); POLY(N METHYLDIETHENEAMINESEBACATE) CO [(CHOLESTERYL OXOCARBONYLAMIDO ETHYL)METHYL BIS(ETHYLENE)AMMONIUM BROMIDE]SEBACATE; POLY(PROPYLENEIMINE) GENERATION 5 DENDRIMER; POLYAMIDOAMINE; POLYMER; POLYPROPYLENEIMINE; PROTEIN BCL 2; SMALL INTERFERING RNA; SUPERMAGNETIC IRON OXIDE; TRIPLEX OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; BREAST CANCER; CANCER THERAPY; CONTROLLED DRUG RELEASE; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; LUNG CANCER; MICELLE; NANOTECHNOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; REVIEW; RNA INTERFERENCE; RNA TRANSLATION;

EID: 84861164250     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800624418     Document Type: Review

References (140)

1. Chabner, B. A.; Roberts Jr., T. G., Chemotherapy and the War on Cancer. Nature Rev. Cancer 2005, 5, 65-72.
2. Greco, F.; Vicent, M. J., Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Advanced Drug Delivery Reviews 2009, 61, (13), 1203-1213.
3. Broxterman, H. J.; Georgopapadakou, N. H., Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations. Drug Resistance Updates 2005, 8, (4), 183-197.
4. Georgopapadakou, N.; Broxterman, H.; Arts, E.; Perfect, J.; Ward, S., Eight years of Drug Resistance Updates. Drug Resistance Updates 2005, 8, (1-2), 1-2.
5. Kakeji, Y.; Oki, E.; Egashira, A.; Sadanaga, N.; Takahashi, I.; Morita, M.; Emi, Y.; Maehara, Y., Phase II Study of Biweekly Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer. Oncology 2009, 77, (1), 49-52.
6. Bathe, O. F.; Ernst, S.; Sutherland, F. R.; Dixon, E.; Butts, C.; Bigam, D.; Holland, D.; Porter, G. A.; Koppel, J.; Dowden, S., A phase II experience with neoadjuvant irinotecan (CPT-II), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer 2009, 9.
7. Shi, J. J.; Votruba, A. R.; Farokhzad, O. C.; Langer, R., Nanotechnology in Drug Delivery and Tissue Engineering: From Discovery to Applications. Nano Lett. 2010, ASAP.
8. Farrell, D.; Alper, J.; Ptak, K.; Panaro, N. J.; Grodzinski, P.; Barker, A. D., Recent Advances from the National Cancer Institute Alliance for Nanotechnology in Cancer. ACS Nano 2010, 4, (2), 589-594.
9. Petros, R. A.; DeSimone, J. M., Strategies in the Design of Nanoparticles for Therapeutic Applications. Nature Review and Drug Discovery 2010, 9, 615-627.
10. Davis, M. E.; Chen, Z.; Shin, D. M., Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery 2008, 7, (9), 771-782.
11. Zhang, L.; Gu, F. X.; Chan, J. M.; Wang, A. Z.; Langer, R. S.; Farokhzad, O. C., Nanoparticles in medicine: Therapeutic applications and developments. Clinical Pharmacology & Therapeutics 2008, 83, (5), 761-769.
12. Terwogt, J. M. M.; Huinink, W. W. T.; Schellens, J. H. M.; Schot, M.; Mandjes, I. A. M.; Zurlo, M. G.; Rocchetti, M.; Rosing, H.; Koopman, F. J.; Beijnen, J. H., Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 2001, 12, (4), 315-323.
13. Maeda, H., Polymer Conjugated Macromolecular Drugs for Tumor-specific Targeting John Wiley and Sons Ltd: 1994; p 95-116.
14. Vasey, P. A.; Kaye, S. B.; Morrison, R.; Twelves, C.; Wilson, P.; Duncan, R.; Thomson, A. H.; Murray, L. S.; Hilditch, T. E.; Murray, T.; Burtles, S.; Fraier, D.; Frigerio, E.; Cassidy, J.; Canc Res Campaign Phase, I. I. I. C., Phase I clinical and pharmacokinetic study of PK1 N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin: First member of a new class of chemotherapeutic agents-Drug-polymer conjugates. Clinical Cancer Research 1999, 5, (1), 83-94.
15. Sirova, M.; Mrkvan, T.; Strohalm, J.; Etrych, T.; Ulbrich, K.; Rihova, B., HPMA-based macromolecular therapeutics reinforce antitumor immunity. Tumor Biology 2007, 28, 86-87.
16. Minko, T.; Kopeckova, P.; Pozharov, V.; Kopecek, J., HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. Journal of Controlled Release 1998, 54, (2), 223-233.
17. Chen, A. M.; Zhang, M.; Wei, D. G.; Stueber, D.; Taratula, O.; Minko, T.; He, H. X., Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug-Resistant Cancer Cells. Small 2009, 5, (23), 2673-2677.
18. Sirova, M.; Strohalm, J.; Subr, V.; Plocova, D.; Rossmann, P.; Mrkvan, T.; Ulbrich, K.; Rihova, B., Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunology Immunotherapy 2007, 56, (1), 35-47.
19. Greco, F.; Vicent, M. J., Polymer-drug conjugates: current status and future trends. Frontiers in Bioscience 2008, 13, 2744-2756.
20. Haag, R.; Kratz, F., Polymer therapeutics: Concepts and applications. Angewandte Chemie-International Edition 2006, 45, (8), 1198-1215.
21. Duncan, R., Polymer conjugates as anticancer nanomedicines. Nature Reviews Cancer 2006, 6, (9), 688-701.
22. Duncan, R.; Ringsdorf, H.; Satchi-Fainaro, R., Polymer therapeutics-polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities (Reprinted from Advances in Polymer Science, vol 192, pg 1-8, 2005). Journal of Drug Targeting 2006, 14, (6), 337-341.
23. Vicent, M. J.; Duncan, R., Polymer conjugates: nanosized medicines for treating cancer. Trends in Biotechnology 2006, 24, (1), 39-47.
24. Li, C.; Wallace, S., Polymer-drug conjugates: Recent development in clinical oncology. Advanced Drug Delivery Reviews 2008, 60, (8), 886-898.
25. Lammers, T., Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Advanced Drug Delivery Reviews 2010, 62, (2), 203-230.
26. Santhakumaran, L. M.; Chen, A.; Pillai, C. K. S.; Thomas, T.; He, H.; Thomas, T. J., Nanotechnology in Nonviral Gene Delivery In Nanofabrication Towards Biomedical Applications: Techniques, Tools, Applications, and Impact, Kumar, C. S. S. R. H., J.; Leuschner, C., Ed. Wiley-VCH: 2005.
27. Richards, S.; Liu, S.-T.; Majumdar, A.; Liu, J.-L.; Nairn, R. S.; Bernier, M.; Maher, V.; Seidman, M. M., Triplex Targeted Genomic Crosslinks Enter Separable Deletion and Base Substitution Pathways. Nucleic Acids Res. 2005, 17, (33), 5382-5393.
28. Seidman, M. M.; Glazer, P. M., The potential for gene repair via triple helix formation. J. Clin. Invest. 2003, 4, (112), 487-494.
29. Braasch, D. A.; Corey, D. R., Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression. Biochemistry 2002, 14, (41), 4503-4510.
30. de Fougerolles, A.; Vornlocher, H.-P.; Maraganore, J.; Lieberman, J., Interfering with Disease: A Progress Report on siRNA-based Therapeutics. Nat. Rev. Drug Discovery 2007, 6, 443-453.
31. Dykxhoorn, D. M.; Lieberman, J., The Silent Revolution: RNA Interference as Basic Biology, Research Tool and Therapeutic. Annu. Rev. Med. 2005, (56), 401-423.
32. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T., Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells. Nature 2001, (411), 494-498.
33. Lysik, M. A.; Wu-Pong, S., Innovations in oligonucleotide drug delivery. J. Pharm. Sci. 2003, 92, (8), 1559-1573.
34. Uprichard, S. L., The Therapeutic Potential of RNA Interference. FEBS Lett. 2005, (579), 5996-6007.
35. Baker, B. F.; Monia, B. P., Novel Mechanisms for Antisense-Mediated Regulation of Gene Expression. Biochim. Biophys. Acta 1999, (1489), 3-18.
36. Crooke, S. T., Molecular Mechanisms of Action of Antisense Drugs. Biochim. Biophys. Acta 1999, (1489), 31-44.
37. Hannon, G. J., RNA interference. Nature 2002, (418), 244-251.
38. Fire, A.; Xu, S.; Montgomery, M. K.; Kostas, S. A.; Driver, S. E.; Mello, C. C., Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans. Nature 1998, (391), 806-811.
39. Saad, M.; Garbuzenko, O. B.; Minko, T., Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. nanomedicine 2008, 3, (6), 761-776.
40. Kleer, C. G.; Cao, Q.; Varambally, S.; Shen, R.; Ota, I.; Tomlins, S. A.; Ghosh, D.; Sewalt, R. G. A. B.; Otte, A. P.; Hayes, D. F.; Sabel, M. S.; Livant, D.; Weiss, M. A.; Rubin, M. A.; Chinnaiyan, A. M., EZH2 is a Marker of Aggressive Breast Cancer and Promotes Neoplastic Transformation of Breast Epithelial Cells. Proc. Natl. Acad. Sci, USA 2003, 100, 11606-11611.
41. Bachmann, I. M.; Halvorsen, O. J.; Collett, K.; Stefansson, I. M.; Straume, O.; Haukaas, S. A.; Salvesen, H. B.; Otte, A. P.; Akslen, L. A., EZH2 Expression Is Associated with High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast. J. Clin. Oncology 2006, 24, 268-273.
42. Medarova, Z.; Pham, W.; Farrar, C.; Petkova, V.; Moore, A., In vivo Imaging of siRNA Delivery and Silencing in Tumors. Nat. Medicine 2007, 13, 372-377.
43. Zaffaroni, N.; Pennati, M.; Daidone, M. G., Survivin as a target for new anticancer interventions. Journal of Cellular and Molecular Medicine 2005, 9, (2), 360-372.
44. Peng, X. H.; Karna, P.; Cao, Z. H.; Jiang, B. H.; Zhou, M. X.; Yang, L., Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1 alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. Journal of Biological Chemistry 2006, 281, (36), 25903-25914.
45. Peng, X. H.; Karna, P.; O'Regan, R. M.; Liu, X. J.; Naithani, R.; Moriarty, R. M.; Wood, W. C.; Lee, H. Y.; Yang, L., Downregulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Molecular Pharmacology 2007, 71, (1), 101-111.
46. Castanotto, D.; Rossi, J. J., The promises and pitfalls of RNAinterference-based therapeutics. Nature 2009, 457, (7228), 426-433.
47. Santhakumaran, L. M.; Chen, A.; Pillai, C. K. S.; Thomas, T.; He, H. X.; Thomas, T. J., Nanotechnology in Nonviral Gene Delivery. In Nanofabrication Towards Biomedical Applications, Eds. C. S. S. R. Kumar, H. J. a. L. C., Ed. Wiley-VCH: Germany, 2005.
48. Juliano, R.; Alam, M. R.; Dixit, V.; Kang, H., Survey and Summary: Mechanisms and Strategies for Effective Delivery of Antisense and siRNA Oligonucleotides. Nucleic Acids Research 2008, 36, 4158-4171.
49. Whitehead, K. A.; Langer, R.; Anderson, D. G., Knocking down Barriers: Advances in siRNA Delivery. Nat. Rev. Drug Discovery 2009, 8, 129-138.
50. Akhtar, S.; Benter, I. F., Nonviral Delivery of Synthetic siRNAs in vivo. J. Clin. Invest. 2007, 117, 3623-3632.
51. Whitehead, K. A.; Langer, R.; Anderson, D. G., Knocking down barriers: advances in siRNA delivery. Nature Reviews Drug Discovery 2009, 8, (2), 129-138.
52. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C., Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecular Pharmaceutics 2008, 5, (4), 505-515.
53. Zamecnik, J.; Vargova, L.; Homola, A.; Kodet, R.; Sykova, E., Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathology and Applied Neurobiology 2004, 30, (4), 338-350.
54. Oliveira, S.; van Rooy, I.; Kranenburg, O.; Storm, G.; Schiffelers, R. M., Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. International Journal of Pharmaceutics 2007, 331, (2), 211-214.
55. Di Guglielmo, G. M.; Le Roy, C.; Goodfellow, A. F.; Wrana, J. L., Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nature Cell Biology 2003, 5, (5), 410-421.
56. Hammond, S. M.; Bernstein, E.; Beach, D.; Hannon, G. J., An RNA-directed Nuclease Mediates Post-transcriptional Gene Silencing in Drosophila Cells. Nature 2000, 404, 293-296.
57. Nykanen, A.; Haley, B.; Zamore, P. D., ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway. Cell 2001, 107, 309-321.
58. Chiu, Y.-L.; Rana, T. M., RNAi in Human Cells: Basic Structural and Functional Features of Small Interfering RNA. Mol. Cell 2002, 10, 549-561.
59. Gary, D. J.; Puri, N.; Won, Y.-Y., Polymer-based siRNA Delivery: Perspectives on the Fundamental and Phenomenological Distinctions from Polymer-based DNA Delivery. J. Controlled Release 2007, 121, 64-73.
60. MacDiarmid, J. A.; Amaro-Mugridge, N. B.; Madrid-Weiss, J.; Sedliarou, I.; Wetzel, S.; Kochar, K.; Brahmbhatt, V. N.; Phillips, L.; Pattison, S. T.; Petti, C.; Stillman, B.; Graham, R. M.; Brahmbhatt, H., Sequential Treatment of Drug-Resistant Tumors with Targeted Minicells Containing siRNA or a Cytotoxic Drug. Nat. Biotech. 2009, 27, 643-654.
61. Yadav, S.; van Vlerken, L. E.; Little, S. R.; Amiji, M. M., Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemotherapy and Pharmacology 2009, 63, (4), 711-722.
62. Kozubek, A.; Gubernator, J.; Przeworska, E.; Stasiuk, M., Liposomal drug delivery: a novel approach: PLARosomes. Acta Biochimica Polonica 2000, 47, 639-649.
63. Ishida, T.; Kirchmeier, M. J.; Moase, E. H.; Zalipsky, S.; Allen, T. M., Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochimica et Biophysica Acta (BBA)-Biomembranes 2001, 1515, (2), 144-158.
64. Gabizon, A., Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Advanced Drug Delivery Reviews 1995, 16, 285-294.
65. Pakunlu, R. I.; Cook, T. J.; Minko, T., Simultaneous Modulation of Multidrug Resistance and Antiapoptotic Cellular Defense by MDR1 and BCL-2 Targeted Antisense Oligonucleotides Enhances the Anticancer Efficacy of Doxorubicin. Pharm. Res. 2003, 20, 351-359.
66. Pakunlu, R. I.; Wang, Y.; Tsao, W.; Pozharov, V.; Cook, T. J.; Minko, T., Enhancement of the Efficacy of Chemotherapy for Lung Cancer by Simultaneous Suppression of Multidrug Resistance and Antiapoptotic Celluar Defences: Novel Multicomponent Delivery System. Cancer Res. 2004, 64, 6214-6224.
67. Siehl, J. M.; Thiel, E.; Schmittel, A.; Hutter, G.; Deckert, P. M.; Szelenyi, H.; Keilholz, U., Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma-Results of a Phase II study. Cancer 2005, 104, (3), 611-617.
68. Pakunlu, R. I.; Wang, Y.; Saad, M.; Khandare, J. J.; Starovoytov, V.; Minko, T., In Vitro and In Vivo Intracellular Liposomal Delivery of Antisense Oligonucleotides and Anticancer Drug. J. Controlled Release 2006, 114, 153-162.
69. Garbuzenko, O. B.; Saad, M.; Pozharov, V. P.; Reuhl, K. R.; Mainelis, G.; Minko, T., Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proceedings of the National Academy of Sciences of the United States of America 2010, 107, (23), 10737-10742.
70. Wang, Y.; Saad, M.; Pakunlu, R. I.; Khandare, J. J.; Garbuzenko, O. B.; Vetcher, A. A.; Soldatenkov, V. A.; Pozharov, V. P.; Minko, T., Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor. Clinical Cancer Research 2008, 14, (11), 3607-3616.
71. Kietzmann, T.; Knabe, W.; Schmidt-Kastner, R., Hypoxia and hypoxia-inducible factor modulated gene expression in brain: involvement in neuroprotection and cell death. European Archives of Psychiatry and Clinical Neuroscience 2001, 251, (4), 170-178.
72. Brune, B.; von Knethen, A.; Sandau, K. B., Transcription factors p53 and HIF-1 alpha as targets of nitric oxide. Cellular Signalling 2001, 13, (8), 525-533.
73. Sandau, K. B.; Zhou, J.; Kietzmann, T.; Brune, B., Regulation of the hypoxia-inducible factor 1 alpha by the inflammatory mediators nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide. Journal of Biological Chemistry 2001, 276, (43), 39805-39811.
74. Livingston, D. M.; Shivdasani, R., Toward mechanism-based cancer care. Jama-Journal of the American Medical Association 2001, 285, (5), 588-593.
75. Shannon, A. M.; Bouchier-Hayes, D. J.; Condron, C. M.; Toomey, D., Tumour hypoxia, chemotherapeutic resistance and hypoxiarelated therapies. Cancer Treatment Reviews 2003, 29, (4), 297-307.
76. Wouters, B. G.; Koritzinsky, M.; Chin, R. K.; Theys, J.; Buijsen, J.; Lambin, P., Modulation of cell death in the tumor micro environment. Seminars in Radiation Oncology 2003, 13, (1), 31-41.
77. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N., Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Science 2003, 94, (1), 15-21.
78. Lee, E.; Na, K.; Bae, Y., Doxorubicin loaded pH sensitive polymeric micelles for reversal of resistant MCF-7 tumor. Journal of Controlled Release 2005, 103, 405-418.
79. Liua, P.; Wang, B.; Li, J.; Qiao, W., Mult-anticancer drugs encapsulated in the micelle: A novel chemotherapy to cancer. Medical Hypothesis 2008, 71, 379-381.
80. Bromberg, L., Polymeric micelles in oral chemotherapy. Journal of Controlled Release 2008, 128, 99-112.
81. Lee, H.; Soo, P.; Liu, J.; Butler, M.; Allen, C., Polymeric micelles for formulation of anticancer cells. Nanotechnology for Cancer Therapy (Amiji, M.M. Ed.) CRC Press, Boca Raton 2007, 317-355.
82. Xiong, X.; Aliabadi, H.; Lavasanifar, A., PEO modified poly (L amino acid) micelles for drug delivery. Nanotechnology for Cancer Therapy (Amiji, M.M. Ed.) CRC Press, Boca Raton 2007, 357-383.
83. Zhu, C. H.; Jung, S.; Luo, S. B.; Meng, F. H.; Zhu, X. L.; Park, T. G.; Zhong, Z. Y., Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMAPCL-PDMAEMA triblock copolymers. Biomaterials 2010, 31, (8), 2408-2416.
84. Cherng, J. Y.; vandeWetering, P.; Talsma, H.; Crommelin, D. J. A.; Hennink, W. E., Effect of size and serum proteins on transfection efficiency of poly(2-dimethylamino)ethyl methacrylate)-plasmid nanoparticles. Pharmaceutical Research 1996, 13, (7), 1038-1042.
85. van de Wetering, P.; Cherng, J. Y.; Talsma, H.; Crommelin, D. J. A.; Hennink, W. E., 2-(dimethylamino)ethyl methacrylate based (co)polymers as gene transfer agents. Journal of Controlled Release 1998, 53, (1-3), 145-153.
86. Convertine, A. J.; Benoit, D. S. W.; Duvall, C. L.; Hoffman, A. S.; Stayton, P. S., Development of a novel endosomolytic diblock copolymer for siRNA delivery. Journal of Controlled Release 2009, 133, (3), 221-229.
87. You, Y. Z.; Manickam, D. S.; Zhou, Q. H.; Oupicky, D., Reducible poly(2-dimethylaminoethyl methaerylate): Synthesis, cytotoxicity, and gene delivery activity. Journal of Controlled Release 2007, 122, (3), 217-225.
88. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J., Vascular-specific growth factors and blood vessel formation. Nature 2000, 407, (6801), 242-248.
89. Kim, K. J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H. S.; Ferrara, N., Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumor-Growth Invivo. Nature 1993, 362, (6423), 841-844.
90. Azzouz, M.; Ralph, G. S.; Storkebaum, E.; Walmsley, L. E.; Mitrophanous, K. A.; Kingsman, S. M.; Carmeliet, P.; Mazarakis, N. D., VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429, (6990), 413-417.
91. Reich, S.; Fosnot, J.; Kuroki, A.; Tang, W. X.; Yang, X. Y.; Maguire, A.; Bennett, J.; Tolentino, M., Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Molecular Vision 2003, 9, (31-32), 210-216.
92. Wang, Y.; Gao, S.; Ye, W.-H.; Yoon, H. S.; Yang, Y.-Y., Codelivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat Mater 2006, 5, (10), 791-796.
93. Wang, Y.; Wang, L.-S.; Goh, S.-H.; Yang, Y.-Y., Synthesis and Characterization of Cationic Micelles Self-Assembled from a Biodegradable Copolymer for Gene Delivery. Biomacromolecules 2007, 8, (3), 1028-1037.
94. Kukowska-Latallo, J. F.; Bielinska, A. U.; Johnson, J.; Spindler, R.; Tomalia, D. A.; Baker, J. R., Jr., Efficient Transfer of Genetic Material into Mammalian Cells Using Starburst Polyamidoamine Dendrimers. Proc. Natl. Acad. Sci, USA 1996, 93, 4897-4902.
95. Dufes, C.; Uchegbu, I. F.; Schatzlein, A. G., Dendrimers in Gene Delivery. Adv. Drug Deliv. Rev. 2005, 57, 2177-2202.
96. Boas, U.; Heegaard, P. M. H., Dendrimers in Drug Research. Chem. Soc. Rev. 2004, 33, 43-63.
97. Samad, A.; Alam, M. I.; Saxena, K., Dendrimers: A Class of Polymers in the Nanotechnology for the Delivery of Active Pharmaceuticals. Current pharmaceutical design 2009, 15, 2958-2969.
98. Ali, M. M.; Yoo, B.; Pagel, M. D., Tracking the Relative In Vivo Pharmacokinetics of Nanoparticles with PARACEST MRI. Molecular Pharmaceutics 2009, 6, 1409-1416.
99. Taratula, O.; Savla, R.; Pandya, I.; Kirkpatrick, P.; He, H. X.; Minko, T., PPI Dendrimers as Potential siRNA Delivery Vehicles for Efficient Cancer Therapy: Structure-Function Relationship. Internat. J. Nanotech. 2010, In Press
100. Taratula, O.; Garbuzenko, O. B.; Kirkpatrick, P.; Pandya, I.; Savla, R.; Pozharov, V. P.; He, H. X.; Minko, T., Surface-Engineered Targeted PPI Dendrimers for Efficient Intracellular and Intratumoral siRNA delivery. J. Control Release 2009, 140, 284-293.
101. Taratula, O.; Garbuzenko, O.; Savla, R.; Wang, Y. A.; He, H. X.; Minko, T., Multifunctional Nanomedicine Platform for Cancer Specific Delivery of siRNA by Superparamagnetic Iron Oxide Nanoparticles-Dendrimer Complexes. Current Drug Delivery 2011, 8, 59-69.
102. Patri, A. K.; Kukowska-Latallo, J. F.; Baker, J. R., Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Advanced Drug Delivery Reviews 2005, 57, (15), 2203-2214.
103. D'Emanuele, A.; Attwood, D., Dendrimer-drug interactions. Advanced Drug Delivery Reviews 2005, 57, (15), 2147-2162.
104. Liu, M. J.; Frechet, J. M. J., Designing Dendrimers for Drug Delivery Pharm. Sci. Tech. Today 1999, 2, 393-401.
105. Vijayanathan, V.; Thomas, T.; Thomas, T. J., DNA nanoparticles and development of DNA delivery vehicles for gene therapy. Biochemistry 2002, 41, (48), 14085-94.
106. Tang, M. X.; Redemann, C. T.; Szoka Jr, F. C., In vitro Gene Delivery by Degraded Polyamidoamine Dendrimers. Bioconjugate Chem. 1996, 7, 703-714.
107. Dennig, J., Gene Transfer in Eukaryotic Cells Using Activated Dendrimers. Top. Curr. Chem. 2003, 2003, 227-236.
108. Chen, A. M.; Taratula, O.; Wei, D. G.; Yen, H. I.; Thomas, T.; Thomas, T. J.; Minko, T.; He, H. X., Labile Catalytic Packaging of DNA/siRNA: Control of Gold Nanoparticles "out" of DNA/siRNA Complexes. ACS Nano 2010, 4, (7), 3679-3688.
109. Chen, A.; Santhakumaran, L. M.; Nair, S. K.; Amenta, P. S.; Thomas, T.; He, H. X.; Thomas, T. J., Oligodeoxynucleotide Nanostructure Formation in the Presence of Polypropyleneimine Dendrimers and Their Uptake in Breast Cancer Cells. Nanotechnology 2006, 17, 5449-5460.
110. Dufes, C.; Uchegbu, I. F.; Schatzlein, A. G., Dendrimers in gene delivery. Adv Drug Deliv Rev 2005, 57, (15), 2177-202.
111. Ren, Y.; Kang, C. S.; Yuan, X. B.; Zhou, X.; Xu, P.; Han, L.; Wang, G. X.; Jia, Z. F.; Zhong, Y.; Yu, S. Z.; Sheng, J.; Pu, P. Y., Co-delivery of as-miR-21 and 5-FU by Poly(amidoamine) Dendrimer Attenuates Human Glioma Cell Growth in Vitro. Journal of Biomaterials Science-Polymer Edition 2010, 21, (3), 303-314.
112. Kaneshiro, T. L.; Lu, Z.-R., Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimerbased nanoglobular carrier. Biomaterials 2009, 30, (29), 5660-5666.
113. Kim, E.; Jung, Y.; Choi, H.; Yang, J.; Suh, J. S.; Huh, Y. M.; Kim, K.; Haam, S., Prostate cancer cell death produced by the codelivery of Bcl-xL shRNA and doxorubicin using an aptamerconjugated polyplex. Biomaterials 2010, 31, (16), 4592-4599.
114. Thorek, D. L. J.; Chen, A.; Czupryna, J.; Tsourkas, A., Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Annals of Biomedical Engineering 2006, 34, (1), 23-38.
115. Lee, J. H.; Lee, K.; Moon, S. H.; Lee, Y.; Park, T. G.; Cheon, J., All-in-One Target-Cell-Specific Magnetic Nanoparticles for Simultaneous Molecular Imaging and siRNA Delivery. Angewandte Chemie-International Edition 2009, 48, (23), 4174-4179.
116. Deng, W. P.; Wu, C. C.; Lee, C. C.; Yang, W. K.; Wang, H. E.; Liu, R. S.; Wei, H. J.; Gelovani, J. G.; Hwang, J. L.; Yang, D. M.; Fu, Y. K.; Wu, C. W., Serial in vivo imaging of the lung metastases model and gene therapy using HSV1-tk and ganciclovir. Journal of Nuclear Medicine 2006, 47, (5), 877-884.
117. Slowing, I.; Trewyn, B. G.; Lin, C. S.-Y., Effect of Surface Functionalization of MCM-41 Type Mesoporous Silica Nanoparticles on the Endocytosis by Human Cancer Cells. J. Am. Chem. Soc. 2006, 128, 14792-14793.
118. Vallet-Regi, M.; Balas, F.; Aros, D., Mesoporous Materials for Drug Delivery. Angew. Chem. Int. Ed. 2007, 46, 7548-7558.
119. Das, S.; Jain, T. K.; Maitra, A., Inorganic-Organic Hybrid Nanoparticles from n-Octyl Triethoxy Silane. J. Colloid Interface Sci. 2002, 252, 82-88.
120. Huh, S.; Wiench, J. W.; Trewyn, B. G.; Song, S.; Pruski, M.; Lin, C. S.-Y., Tuning of Particle Morphology and Pore Properties in Mesoporous Silicas with Multiple Organic Functional Groups. Chem. Comm. 2003, 2364-2365.
121. Slowing, I. I.; Trewyn, B. G.; Giri, S.; Lin, V. S.-Y., Mesoporous Silica nanoparticles for Drug Delivery and Biosensing Applications. Adv. Funct. Mater. 2007, 17, 1225-1236.
122. Hom, C.; Lu, J.; Tamanoi, F., Silica Nanoparticles as a Delivery System for Nucleic Acid-based Reagents. J. Mater. Chem. 2009, 19, 6308-6316.
123. Torney, F.; Trewyn, B. G.; Lin, V. S. Y.; Wang, K., Mesoporous Silica Nanoparticles Deliver DNA and Chemicals into Plants. Nature Nanotech. 2007, 2, 295-300.
124. Meng, H.; Monty Liong, Tian Xia, Zongxi Li, Zhaoxia Ji, Jeffrey I. Zink, and Andre E. Nel, Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line. ACS Nano 2010, ASAP.
125. Khan, M. K.; Nigavekar, S. S.; Minc, L. D.; Kariapper, M. S. T.; Nair, B. M.; Lesniak, W. G.; Balogh, L. P., In vivo Biodistribution of Dendrimers and Dendrimer Nanocomposites-Implications for Cancer Imaging and Therapy. Tech. Cancer Res. Treatment 2005, 4, 603-613.
126. Balogh, L. P.; Nigavekar, S. S.; Cook, A. C.; Minc, L.; Khan, M. K., Development of Dendrimer-Gold Radioactive Nanocomposites to Treat Cancer Microvasculature. PharmaChem 2003, 2, 94.
127. Balogh, L. P.; Nigavekar, S. S.; Sung, L. Y.; Balogh, P.; Shi, X. Y.; Cook, A. T.; Minc, L. D.; Khan, M. K., Development of Radioactive Gold-Dendrimer Nanocomposite Devices to Treat Tumor Microvasculature: Synthesis and Biodistribution. J. Nuc. Med. 2003, 44, 305P-306P.
128. Gottesman, M. M.; Fojo, T.; Bates, S. E., Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters. Nature Rev. Cancer 2002, 2, 48-58.
129. Harris, A. L.; Hochhauser, D., Mechanisms of Multidrug Resistance in Cancer-Treatment. Acta Oncologica 1992, 31, (2), 205-213.
130. Di Nicolantonio, F.; Mercer, S. J.; Knight, L. A.; Gabriel, F. G.; Whitehouse, P. A.; Sharma, S.; Fernando, A.; Glaysher, S.; Di Palma, S.; Johnson, P.; Somers, S. S.; Toh, S.; Higgins, B.; Lamont, A.; Gulliford, T.; Hurren, J.; Yiangou, C.; Cree, I. A., Cancer cell adaptation to chemotherapy. BMC Cancer 2005, 5.
131. Wang, Y.; Gao, S.; Ye, W. H.; Yoon, H. S.; Yang, Y. Y., Codelivery of Drugs and DNA from Cationic Core-Shell Nanoparticles Self-Assembled from a Biodegradable Copolymer. Nat. Mater. 2006, 5, 791-796.
132. Scagliotti, G. V.; Novello, S.; Selvaggi, G., Multidrug resistance in non-small-cell lung cancer. Annals of Oncology 1999, 10, 83-86.
133. Nakamura, M.; Abe, Y.; Katoh, Y.; Oshika, Y.; Hatanaka, H.; Tsuchida, T.; Yamazaki, H.; Kijima, H.; Inoue, H.; Ueyama, Y., A case of pulmonary adenocarcinoma with overexpression of multidrug resistance-associated protein and p53 aberration. Anticancer Research 2000, 20, (3B), 1921-1925.
134. Hsia, T. C.; Lin, C. C.; Wang, J. J.; Ho, S. T.; Kao, A., Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 2002, 180, (3), 173-179.
135. Wang, J.; Huang, M.-H.; Zeng, Z.-H.; Fang, H.-X.; Yang, M.-S., Gene Expression Profiling in Multidrug Resistant KB Cells Using cDNA Microarrays. Chin. J. Cancer Res. 2002, 14, 5-10.
136. Ougolkov, A. V.; Bilim, V. N.; Billadeau, D. D., Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2. Clin. Cancer Res. 2008, 14, 6790-6796.
137. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G. L.; Watson, N.; Kiziltepe, T.; Sasisekharan, R., Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436, (7050), 568-572.
138. Rihova, B.; Etrych, T.; Sirova, M.; Kovar, L.; Hovorka, O.; Kovar, M.; Benda, A.; Ulbrich, K., Synergistic Action of Doxorubicin Bound to the Polymeric Carrier Based on N-(2-Hydroxypropyl) methacrylamide Copolymers through an Amide or Hydrazone Bond. Molecular Pharmaceutics 2010, 7, (4), 1027-1040.
139. Park, J. O.; Lopez, C. A.; Gupta, V. K.; Brown, C. K.; Mauceri, H. J.; Darga, T. E.; Manan, A.; Hellman, S.; Posner, M. C.; Kufe, D. W.; Weichselbaum, R. R., Transcriptional control of viral gene therapy by cisplatin. The Journal of Clinical Investigation 2002, 110, (3), 403-410.
140. Okuda, T.; Tominaga, K.; Kidoaki, S., Time-programmed dual release formulation by multilayered drug-loaded nanofiber meshes. Journal of Controlled Release 2010, 143, (2), 258-264.